Ranirestat for the management of diabetic sensorimotor polyneuropathy - Wikidata - wikimedia - TriplyDB

Ranirestat for the management of diabetic sensorimotor polyneuropathy

Ranirestat for the management of diabetic sensorimotor polyneuropathy

http://www.wikidata.org/entity/Q28241270

about

Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function.Four-year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation.Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters.The evolving natural history of neurophysiologic function in patients with well-controlled diabetes.AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.The effects of capillary dysfunction on oxygen and glucose extraction in diabetic neuropathy.Update on the management of diabetic polyneuropathies.Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.Emerging drugs for diabetic neuropathy.Diabetic neuropathy: cellular mechanisms as therapeutic targets.Whither pathogenetic treatments for diabetic polyneuropathy?Diabetic neuropathy and oxidative stress: therapeutic perspectives.Evaluation of ranirestat for the treatment of diabetic neuropathy.Neurologic complications of diabetes.Efficacy of α-lipoic acid in diabetic neuropathy.Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.The wound/burn guidelines - 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene.Antioxidant strategies in the management of diabetic neuropathy.NHC-Catalyzed Asymmetric Synthesis of Functionalized Succinimides from Enals and α-Ketoamides.Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.Metabolic Syndrome and Neuroprotection.

P2860

Q30239828-BF2C3630-0F2E-42AF-A828-90037FB47E6B Q33633642-C8C2EDF9-26C9-4AE3-9162-329677E7CAAA Q34434392-E50CB17C-2EEE-4A66-9341-1068129420E8 Q34637674-3CC33980-AEC0-4431-921E-DA646B16D19B Q34777951-C6FDAE8A-0E63-497D-9DDE-F82F28F1FB3C Q35141326-F8EEBED7-2734-41E1-9BDA-F23D7682551F Q35153023-CC7BC661-1DFD-4284-9065-D6C6192CAAE4 Q35178801-FAAD7760-B71D-40CD-87EB-964D1441002D Q35179226-595C299F-A3C2-4B42-9FE0-FD10523544BA Q35179957-03C661D5-EF11-4C65-ADBE-B93CA4711A9E Q36293649-B1A01C05-BB2F-42BF-BB13-64A92E695863 Q36329924-F2B6E6B7-07ED-4E33-AEA7-86D84441AC56 Q36532024-AA6E960E-15DC-4408-8DF4-3EE7DB701708 Q37783301-1FC12E08-7AEB-4833-A20E-8D2B0D8F2B9A Q37930962-4C6127E8-CF9C-4301-936C-2F861C3EDD8E Q38079186-1E73E5BA-E2F9-4D15-833A-E7C6D1A1E57D Q38112117-C35AF1FC-62B8-458E-8702-5FBE608F2446 Q38208484-67F0A11A-4BB4-4A87-BB1E-5479039D55E2 Q38210942-5B7B8579-7E71-42C3-B7A5-14EDEFD9A4D6 Q38266297-6B524960-AFD8-4D11-A987-5D5EAB9C8813 Q38798588-E96A5C09-FB1D-4DFD-8C99-E10E61E68792 Q40757188-BE81CF6D-6C0B-4B71-80B3-64A84910B36A Q42180667-279B55B9-D800-48CD-AB17-44F3A7D93390 Q43170728-DC625EF1-36C5-4299-8F6B-F02EF85DF6F9 Q46207930-86D09831-1868-43CA-92D5-907C18745442 Q47978551-64AC7803-6E6E-45F9-9B63-52BDB9055783 Q53687232-F768AC1B-31B8-4858-BF60-844CB6D97A3F

P2860

Ranirestat for the management of diabetic sensorimotor polyneuropathy

http://www.wikidata.org/entity/Q28241270

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@ast

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@en

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@nl

type

label

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@ast

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@en

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@nl

prefLabel

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@ast

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@en

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@nl

P1433

Q28241270-97E720F8-AB04-4694-AA20-C676EDB484E1

P1476

Q28241270-6A6B64DB-5F3F-47F9-A85A-954C6752F7AF

P2093

Q28241270-7793E2B0-6BD9-4CC8-8EDA-C869F2F80361

Q28241270-7D4BA05E-EB72-4532-B625-EE4E80CF5741

Q28241270-B63D832A-A3BA-4689-BFD4-7707E16412BC

P2860

Q28241270-05C8867E-011D-4F5B-8CBA-3EC625775071

Q28241270-08161772-9A9A-4135-AF43-0A68FAB1F0D8

Q28241270-12ADFC01-CC3E-474F-A67A-B1BFC4F9E488

Q28241270-3D237C42-1905-4403-80F0-BA6A5E8BB680

Q28241270-4A2392D2-070D-4CD8-9AEB-E52F68794734

Q28241270-605A0561-A553-4FA9-BC6D-AFD77E53E75E

Q28241270-675502FD-AEA3-480B-9EBF-D9309F129300

Q28241270-7F6F379A-A202-4D9E-98CE-623DE27C32D8

Q28241270-B2E64C93-4BFA-461A-B5CC-8DA6F90CC7A0

P304

Q28241270-BA2A8EFC-286F-434F-B704-68CB67A58141

P31

Q28241270-07ADA5E0-26E2-493B-8CE0-D0BD29E993C7

P356

Q28241270-8A789EDC-C26D-44E0-A106-7BD119C98CB0

P407

Q28241270-DB23C678-E060-4FEF-8F0E-54F3D5D2515B

P433

Q28241270-05E88F3C-C879-4AFC-8B8E-78C074B41E45

P478

Q28241270-199454C2-FB49-48FD-B305-1773C302B1F4

P50

Q28241270-F7F644EC-5580-44B6-96AF-407F53DFC316

P577

Q28241270-B0B1007C-1A94-4F65-A1EE-A351E5C07E75

P5875

Q28241270-53DC8DD6-F739-4DE5-A1AE-EEE79C8B6940

P698

Q28241270-F4DE69C8-9D22-4AC4-BA49-1F1F37E7D6BF

P932

Q28241270-2939C3C3-2999-456E-8E18-7ED8AD87542B

P356

P1433

P1476

Ranirestat for the management of diabetic sensorimotor polyneuropathy

@en

P2093

Robert Buchanan

http://www.w3.org/2001/XMLSchema#string

Sasagu Tomioka

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Hirose

http://www.w3.org/2001/XMLSchema#string

P2860

Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy.

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

Polyol pathway and diabetic peripheral neuropathy.

Clinical trials of diabetic neuropathy: past, present, and future.

Aldose reductase inhibitors: the end of an era or the need for different trial designs?

Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.

Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.

Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.

The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort.

P304

1256-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC08-2110

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24278103

http://www.w3.org/2001/XMLSchema#string

P698

19366965

http://www.w3.org/2001/XMLSchema#string

P932

2699746

http://www.w3.org/2001/XMLSchema#string